The enthusiasm with which precision medicine has been embraced over the past 15 years has obscured the fact that the evidence base for biomarker-driven assessments, in particular for next generation sequencing (NGS), is limited. This applies both to the comparative performance of the various assessment tools as well as to the impact of biomarker driven decisions at the patient level. Where a genetic test is being evaluated there are five key questions a formulary committee should ask when assessing whether or not to recommend coverage and reimbursement for the test in target patient populations:
INTRODUCTION
A major, if not the principal objection, to precision medicine interventions is the lack of a robust and comprehensive evidence base to support claims that the new paradigm will materially improve patient outcomes and, hopefully, reduce costs 1 2 . Faced with a dearth of evidence that claims for precision medicine interventions are credible, evaluable and replicable, health systems are understandably reluctant to embrace this paradigm.
In many respects, the lack of evidence to support claims in precision medicine and the reluctance to underwrite tests both for older style genomic targeting and the current flavor of the month, next generation sequencing (NGS), is little different from the lack of evidence for claims in traditional pharmaceutical products. More specifically: the lack of claims that are credible, the lack of claims that are evaluable and the lack of claims that can be replicated 3 4 . Formulary committees and other health care decision makers are asked to take on board such claims. These include modeled extrapolations from short-term phase 3 trials as well as the absurd lifetime cost-per-QALY models favored by groups in the US such as the Academy of Managed Care Pharmacy (AMCP) and the Institute for Clinical Effectiveness Research (ICER) and their progenitor the National Institute for Care and Health Excellence (NICE) reference case in the UK 5 6 7 . At the same time, journal editors seem wedded to support the proliferation of lifetime cost-per-QALY models 8 9 10 . Understandably, there is little evidence to suggest that these models actually influence formulary decisions in the US.
Central to the demand for claims that are credible, evaluable and replicable is the issue of clinical utility: the ability of a screening or diagnostic test to support diagnosis, treatment interventions, outcomes, disease management and prevent or ameliorate adverse health outcomes' 11 12 . In precision medicine the test platform is the treatment gatekeeper: the choice of intervention relies upon the accuracy of the test while c claims for clinical utility rest upon test performance. The National Institutes of Health -Department of Energy Task Force on Genetic Testing reporting in 1997 defined the clinical utility of a test as 'the balance of benefits to risks' 13 . While there is obviously a debate as to how broadly the benefits of testing are to be defined, there is agreement that the primary benefit is the ability of the test to inform clinical practice.
From a public health perspective, the evidence to support health impacts is a critical input to setting public priorities and evaluating clinical utility, with the caveat that these must be evidence based. There is no inherent utility in a test unless patients in targeted groups have access to that test and claims based on that test can be evaluated. The acceptance or otherwise of a test should not rest solely on claims for analytical or clinical validity. Rather the test outcomes should be evaluated against standards that apply to claims for pharmaceuticals: are the claims made for the test in clinical practice credible, evaluable and replicable? In other words, does evidence for the test (or more broadly, the test) meet the standards of normal science 14 15 .
If the standards of normal science are applied then we might usefully point to a list of core questions that a formulary committee, health care decision or professional clinical group might ask before approving a particular test for reimbursement or inclusion in a treatment guideline. These are:
(i) has the test met required standards for analytic and clinical validity? (ii) has the test been evaluated against competing tests for analytic and clinical validity? (iii) have the test claims for outcomes and costs in target treating populations met standards for credibility, evaluation and replication? (iv) has the test been accepted as part of the standard of care for patient management in the target disease state? (v) has the introduction of the test improved outcomes, including survivorship, adverse events, quality of life and costs, in the targeted population compared to the standard of care
There is no reason why a formulary committee of other health decision maker should assume that making a NGS test available, even if restricted to target population groups within disease states, will necessarily improve outcomes. After all, there are questions of the uptake of tests ordered by physicians, how a physician implements the test therapy recommendations, adherence and persistent with therapy choices (which may involve complex polytherapy) and the timeframe over which the outcomes for treated patients are monitored.
Once rates of uptake and implementation, together with adherence and persistence with therapy are factored into the assessment, the result from a well-designed, protocol driven observational study may conclude that the outcomes for the target group are inferior to those with the standard of care.
Claims that the outcomes will inevitably be better because they address the issue of tumor heterogeneity may simply evaporate in clinical practice.
The onus is on the test developer or vendor to ensure that there is feedback to health systems, treating physicians and patients that it is worth investing in an NGS test; and, possibly more to the point, that investing in their test is more costeffective than an investment in any one of a number of competing NGS tests. There are two reasons for this: (i) tests may differ in their platform, process and structure and (ii) there is no necessary expectation that different tests will generate similar recommendations for matching pharmaceutical compounds to genetic markers or that the same genetic markers will be identified. Claims for test performance and outcomes from their application must, therefore, be comparative.
Care must be taken, however, in establishing the basis for NGS test comparison (or a comparison against the standard of care). Irrespective of whether or not the assessment is through a randomized clinical trial (RCT)(e.g., an umbrella trial -see below) or through a prospective, protocol driven observational study, the focus is on the response by patients to the recommended therapies driven by the NGS platform. Matching therapies to mutations may result in a recommendation for a monotherapy matched to a single mutation (or cluster of mutations) or more complex polytherapy choices matched to a different cluster of mutations.
Assessments, therefore, should be in terms of the various therapy choices not just on the expressed mutations. One approach, given the inherent heterogeneity of mutations within tumor types is to focus the assessment on the most frequently reported mutation clusters, defined at the level of the individual patient enrolled in the study. The study may, for example, recruit patients in the top 5 or 10 most frequently reported mutation clusters with their associated therapies. These clusters would define the treatment arms within an RCT design or the selection of patients to be tracked in an observational study. The advantage of the observational study is that the starting point could be physicians who request a test, following through on those physicians who implement (or attempt to implement) the recommendations. Needless to say, both RCTs and observational assessments would have to be disease specific, focusing on target populations within the care pathway. After all, claims for one NGS test platform in one target population is no guarantee that a similar response would be expected in in another disease state.
Where a modeled claim accompanies a formulary submission for a NGS test, the model should attempt to capture
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3 treatment pathways defined in terms of the standard(s) of care and the most frequently reported mutation and hence therapy clusters. Unfortunately, with the limited data yet available on therapy cluster outcomes from either RCTs or observational studies this is difficult to accomplish. We have yet to see the expected wave of extrapolated lifetime costper-QALY (quality adjusted life year) precision medicine decision models to support claims from competing NGS platforms. Models that claim that an 'acceptable' accuracy response threshold from a NGS test demonstrates that the sponsor's test will, with appropriate corrections for structural and parameter uncertainty, together with a judicial choice of Markov framework, lead to increased survival, less toxicity, improved quality of life and lower costs in a target population.
Presenting non-evaluable modeled claims that the up-front cost of the genomic test and potentially subsequent tests to check the course of the disease and patient response should be seen as sufficient justification for investing in an NGS test are unacceptable. Attempting to justify the cost-effectiveness of an NGS test through modeling, even if the model generates cost-per-QALY estimates appropriately falling below the magic $50,000 threshold is also not acceptable. Just as in the case of drug products, the claims made will either lack credibility (e.g., cost-per-QALY saved over the lifetime of the patient cohort), will be difficult if not impossible to evaluate with existing data (QALY claims again) and, by extension, be impossible to replicate. In order to forestall such an eventuality, it is important that health care decision makers to set standards for claims credibility, evaluation and replications for NGS tests. The losers in these scenarios will be health systems. They will be asked to support reimbursement for the test while treating physicians will be reluctant to order or implement test claims given the limited evidence for outcomes and costs. The fact that treatment guidelines may recommend genomic assessments at particular disease stages is no guarantee that they will be followed through or their recommendations for drug repositioning acted on. Tests may be ordered and the results put to one side.
The absence of credible, evaluable and replicable claims for drug products in formulary submissions was the genesis behind the recently published proposed guidelines for formulary evaluation developed by the Program in Social and Administrative Pharmacy at the University of Minnesota 16 . The proposed guidelines, while not rejecting modeled claims for clinical comparisons and cost-effectiveness, ask that the claims submitted meet the standards of normal science. To support this, manufacturers making a submission were asked to submit a protocol detailing how the claims were to be assessed and reported back to the formulary committee in a meaningful timeframe. At the same time, even if the manufacturer could claim that it had undertaken such an exercise with another health system and could produce the results as, hopefully, a peer reviewed publication, the option was still open for the health system to request the manufacturer to support a further claims assessment study.
Replication of test claims is, in many ways, the critical issue. Apart from the obvious point that the process of conjecture and refutation underpins our notion of scientific progress (and has done for last least last 350 years -or earlier if we accept the contributions of Francis Bacon 17 ), there is a long standing concern with the absence of studies that are directed to replicating claims from clinical trials and, where such efforts have been undertaken, the limited evidence for claims replication. In the case of tests, formulary committee should be insistent that, in approving and reimbursing a test, evidence is presented that the molecular targets identified, their distribution and claims for clinical impact can be replicated in target populations.
COMMENTARY OUTLINE
The first part of this commentary addresses the issue of current evidentiary standards for evaluating NGS platforms and, more generally, diagnostic tests. Standards proposed by NICE under the Diagnostic Assessment Programme (DAP) are reviewed. These standards are of interest, not only because they point to the importance of identifying the place of a test in therapy for a target population but they link claims for test accuracy to establishing a modeled cost-per-QALY case for the test. At the same time, it is important to address the critical importance (which NICE emphasizes) of ensuring that evidence presented is robust and meets accepted standards in master protocol trial design, and that the test have been approved by responsible agencies.
As a major theme in this commentary is on the need to evaluate tests that are specific to target populations, the commentary then addresses the importance of identifying the characteristics of the target population and the expected place of a test in the treatment pathway. It is argued that it is unwise to expect blanket approval for an NGS test across target populations in disease areas. Rather, health care decision makers should insist on robust evidence from both clinical trials and observational studies to demonstrate that the test has claims relevant to that group and the stage of disease.
The first step in developing a robust case for any test is to ensure that the test meets standards for analytical and clinical validity. These issues are reviewed from the perspective of both the Center for Medicare and Medicaid Services (CMS) and the Food and Drug Administration (FDA). The issue is whether or not platform NGS tests should be seen as medical devices. If they are (as seems likely) the
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4 question is what standards and possible monitoring will the FDA require to approve these tests?
In addition to possible standards for individual NGS test approval, further issues that are addressed are (i) whether or not NGS test platforms should be compared in terms of both their accuracy and the prognostic claims made for linking mutations to drug products and (ii) the standards that would be expected not only for integrating NGS test recommendations in treatment guidelines. It would be possibly unwise, given issues of efficacy and safety, for treatment guidelines to indicate that any NGS test may be appropriate at a particular point in a treatment pathway. Professional groups may wish to nominate specific NGS platforms with a recognized evidence-based contribution to therapy choices alongside the standard of care. Professional groups should indicate why a particular platform is recommended along with details on the platform structure and standard operating procedures in place for curating and updating the platform.
The commentary details recommended evidentiary standards for both clinical trials and observational studies that support claims for test performance in target populations. These would support modeled claims for the test. Where modeled claims and claims from trials and observational studies are presented these should apply (i) to the overall test performance and (ii) the proposed treatment pathways defined by the recommended monotherapy and polytherapy therapy choices linked to observed mutation clusters.
The commentary concludes by detailing (i) a proposed submission format for an NGS test and (ii) a list of 40 questions that a formulary committee should consider in evaluating the submission. As emphasized above, the claims made should be credible, evaluable and replicable. The submission should be accompanied by a protocol to describe how the prognostic claims from the test might be evaluated. The protocol should take into account mutation heterogeneity within, for example, tumors and whether the test should be re-administered given tumor progression. The protocol should describe how it is proposed to provide feedback to the health system as well as feedback on enhancements or modifications to the NGS platform.
THE NICE DIAGNOSTIC ASSESSMENT PROGRAMME
A useful reference point in considering the evidence standards for formulary submissions to support approval and reimbursement of a test is the DAP introduced by NICE in the UK in 2011 18 . Although the program process and conclusions regarding clinical and cost-effectiveness are focused on the assessment and implementation of the test within the National Health Service (NHS) the DAP is relevant for manufacturers in the US. Manufacturers may on the one hand be considering the UK as a potential market will have to meet DAP standards while on the other hand there may be groups in the US (e.g., the ICER) who may take the opportunity to apply their NICE-derived willingness-to-pay methodology to make recommendations for the costeffectiveness of competing tests. When a submission is requested by NICE, it is typically referred to an external assessment group who develop a diagnostics assessment report for review by stakeholders (defined in the assessment scope). A final review and report is prepared by NICE and a diagnostic guidance drafted. The draft guidance is reviewed, issues resolved and then published by NICE for the NHS.
While the NICE process is a useful benchmark, it is unlikely that a health system in the US (other than a government agency) would have the resources to undertake such an extensive review. Also, given the lack of interest in QALY measures, it is unlikely that a reference case modeling would resonate with health system decision makers. The questions proposed here are considered more in line with what is feasible in the US environment.
EVIDENTIARY STANDARDS FOR A TEST SUBMISSION
The evidence to support claims for analytical validity, clinical validity and outcomes must conform to accepted standards. If these standards are not met, the test submission should be returned to the manufacturer. Recommended standards would include reporting:
(a) Diagnostic Accuracy and Quality
Diagnostic Accuracy: All studies referenced to support claims for diagnostic accuracy for the target test and comparators should be evaluated against the STARD 2015 (Standards for Reporting of Diagnostic Accuracy Studies) statement 19 . Each study reported should be scored.
Quality Assessment and Bias: all studies referenced to support claims for diagnostic accuracy should also be appraised for quality and bias against the QUADAS-2 tool (Quality Assessment of Diagnostic Accuracy Studies) 20 . Each study reported should be scored.
(b) Systematic Reviews
Whenever a systematic review is requested to support the test and comparator evidence base it must conform to the PISMA-P 2015 standards 21 . Apart from the usual databases (e.g. PubMed), reference should also be made for reviews focused on the CDC Public Health Genomics Knowledge Base 22 .
(c) Reporting Randomized Trials
Reporting of results from randomized clinical trials of test performance should conform to the Consolidated Standards of Reporting Trials (CONSORT) 23 . This is a standard format for reporting on trial organization, analysis and interpretation. The CONSORT Statement comprises a 25-item check list and flow diagram to record the progress of patients through the trial.
(d) Evidence Hierarchy
Claims for the efficacy or effectiveness of tests in clinical practice must be founded on high quality and bias-free evidence. Where a submission has undertaken a systematic review or relies upon individual studies to support credible, evaluable and replicable claims the evidence presented should be assessed against the standards established within the Grading of Recommendations Assessment, Development and Evaluation (GRADE) working groups. The GRADE framework has superseded earlier proposals for the ranking of evidence (which typically ranks from randomized trials through to observational studies and anecdotal, key opinion leader evidence) to a more flexible evidence hierarchy addressing the quality of evidence for individual outcomes. Specifically: bias, inconsistency, indirectness, imprecision and publication bias 24 .
The GRADE framework is intended to apply to metaanalyses from systematic reviews but can be applied to individual studies or non-quantitative syntheses. All recommendations are 2A unless otherwise noted
The importance of evidence standards in precision medicine claims should not be understated. If the application of NGS (and presumably the generations after that) is to be accepted it is crucial that we have publicly accessible, comprehensive, structured, transparent and bias-free evidence that support both claims development from analytical and clinical validations but subsequent clinical utility claims; claims that are credible, evaluable and replicable. Comparative and systematic reviews are central to this process: comparative because the choice of a test and a belief in the validity of the test is critical to its acceptance by treating physicians as an integral part of the process of care, and systematic because we require the accumulation of evidence from well conducted and credible effectiveness studies to support patient involvement in treatment decisions.
If the hope is that a specific NGS platform be recognized and included as an element in a treatment guideline, then the NCCN standards should be built into any research program to support that platform.
It is essential to recognize and accommodate the dynamic nature of NGS test development. Test platforms are typically in a process of continual upgrading as new evidence is presented for linkages, pathways and targeted therapies. To support this process manufacturers should be asked (possibly as part of annual or bi-annual test reviews) to confirm test performance as part of an ongoing process of re-evaluation and replication in target populations.
Master Protocol Trials
The standards proposed by GRADE and EPC for the evaluation individual trials and systematic reviews apply not only to the phase 2/3 classical randomized controlled trials in drug development and post market entry phase 4 effectiveness trials, but apply with equal force to the trials directed to supporting evidence claims in precision medicine. These socalled master protocol trials include basket trials, umbrella trials, hybrid trials and platform trials 28 . These trial designs have been prompted by the heterogeneity that exists between patients within, for example, a given tumor type and also the heterogeneity that exists within an individual with tumor evolution and metastasis.
Master protocols are an essential part of the process of translating molecular evaluation and genomic target matching into clinically relevant outcomes 29 . These targets include both on-label and off-label prescription of approved compounds as well approval of investigational compounds developed as a result of NGS tests. While off-label matching is suggestive, ad hoc claims from clinical practice and systematic reviews of the literature are no substitute for trial based assessments.
A credible and replicable evidence base driven by master protocols is also a potentially significant contributor to identifying the appropriate target mutation pathway. A test potentially identifies relevant multiple molecular aberrations by disease stage. This drives the choice faced by the treating physician in options for actionable single drug or multiple drug combinations. Faced with a number of potentially competing therapies that match to a mutation, prior assessment may also suggest an optimal treatment to support prognostic claims. Indeed, in the early stages of NGS platform modelling, the most important contribution may be to suggesting a hierarchy of target drug and drug combinations for master protocol trials.
Understandably, in the absence of a well-documented, high quality and coherent evidence base, physicians and patients will be reluctant implement NGS recommendations. Prognostic claims that match mutation to therapy are no different in principal from classical drug claims. They should not be taken at face value. One of roles of a health system is to act as gatekeeper to ensure that these claims merit attention in clinical practice. This applies not only to the NGS test overall but to the individual prognostic claims. After all, support for one prognostic claim may be obscured by indifferent results for other prognostic claims within the proposed set of mutation and therapy linkages. Capturing heterogeneity is no guarantee of test performance for the individual therapy pathways.
The common element in master protocol trials is to utilize a centralized screening test platform with a common protocol format for biomarker-driven sub-studies within the target population. This allows multiple parallel drug studies that replace the traditional (time consuming and wasteful) independent classical single target phase 1 through 3 structures where a strong sub-group effect can be masked by a weak overall effect. In classical trial implementation post facto identification of sub-groups usually generates suggestions rather than hypotheses as the sub-sample is typically underpowered. In master protocol designs the substudies can be flexible in their design to include multi-phase designs to match experimental drugs or the standard of care. The ultimate objective is to confirm the predictive role of the biomarker.
Basket Trial Designs
A basket trial is a master protocol where patient eligibility is defined by the presence of a particular biomarker or alteration rather than, for example, a particular cancer type. The claim is that response can be predicted from a tumor's molecular characteristics matched to a target therapy (or therapies) independent of the tumor histology. As the standard of care will vary across tumor types, it is unusual to find a standard of care control arm.
The principal objection to the basket trial design, at least from the perspective of a formulary committee, is that it says nothing about the overall benefits of introducing that test into clinical practice within single types or classes of cancer for target populations by stage of disease. From the perspective of overall clinical benefit and the potential costeffectiveness of the target therapy the evidence is incomplete and may, in fact, be misleading in failing to capture potential interactions between target therapies in patient groups.
Umbrella Trial Designs
In contrast to the basket trial, an umbrella trial focuses on a single type or class of cancers. The tumor is centrally screened and patients are assigned to molecularly defined sub-groups where they can be randomized and matched against the standard of care pathway. The presence of a single test, the randomization to target therapies and the standard of care for sub-trials, together with the ability to establish response, potential interactions, the impact of comorbidities and demographic factors within a guideline recommended treatment pathway for a specific cancer makes the umbrella trial attractive to formulary committees. Again, however, the formulary committee will need to be assured that the test is accurate and has been evaluated against comparator tests in agree target populations.
Platform and Hybrid Trial Designs
Platform designs are a randomized design with a common control arm and experimental arms defined by molecular type. Management of the platform allows therapies to be added or dropped through adaptive randomization to reduce overall sample size and improve efficiency. Again, unless the platform design captures the range of biomarkers and manages therapies against those biomarkers, it is difficult to see the attraction of this design to formulary committees. A hybrid trial is one where there is a mix of umbrella and basket designs capturing combinations of histologies and molecular aberrations.
Although standards have yet to be agreed for the reporting and assessment of master protocol trials, from the perspective of test choice, the umbrella trial is of particular interest. However, the results of a single umbrella trial only reflect the ability of the test to assign patients to molecular sub-types. Claims for the performance of target therapies against the standard of care will depend on the performance of the test against comparator tests in the accuracy of patient assignment and the ability of the test to match potentially high response therapies to those molecular markers.
APPROVAL STATUS OF COMPETING TESTS
It would be assumed by the formulary committee that the tests submitted (proposed and comparator tests) have been approved, either by the FDA or CMS or, given the present uncertainty over the responsible agency given the moves by the FDA to label tests as medical devices, a successor agency.
The submission should detail whether the test has received regulatory or other approvals in the US or in overseas jurisdictions. Where approvals have been given the manufacturer should indicate whether the test: (i) has been approved only for specific targeted disease states; (ii) whether the material submitted to treating physicians has been approved by the regulatory agency (e.g., a restriction on reporting off-label variant matches); (iii) whether any restrictions or monitoring requirements have been required by a regulatory agency for toxicity or adverse events; and (iv) whether the test has been approved for inclusion in a professionally recognized treatment guideline (e.g., to meet NCCN recommendation standards).
TARGET POPULATION FOR THE TEST
As describe below in the context of the FDA reference standard for diagnostic tests, the target population for any NGS test assessment must be a target population that meets commonly accepted clinical and diagnostic criteria. If the target group is represented by the stage of disease, then recruitment to the target group for NGS evaluation and claims evaluation must conform to that definition. This allows both for comparisons between claims in that target population from competing tests as well as replication of claims made for that target population in other health jurisdictions. It is most unlikely (and inadvisable) for a health system to give the developer or vendor of an NGS test an 'open season' remit to market the test across target patient groups (or ad hoc patients) in different disease states.
As will be detailed below, the test has to be considered from the perspective of the anticipated benefits and costs that it confers on the target treating population within a specific disease state. Approval for a test to be reimbursed should be disease state specific. The approval should be linked to a management strategy where the test complements and is integral to initial diagnosis, disease staging and assessing relapse and resistance to the standard of care within that disease state. The criteria for introducing, interpreting and implementing a test and its recommendations should be detailed as part of the management strategy.
To date, the FDA has endorsed a number of companion diagnostics where the target population is well defined. However, in many cases the claims for the test are much wider, arguing for example that test is appropriate across a number of disease states (e.g., small population nonresponsive cancers).
The promise of NGS tests is, of course, only a first step to the acceptance of a particular test type as an integral and reimbursed element in the standard of care for specific cancer types and other diseases. Claims, for example, for maximal inhibition of viability and proliferation in tumor endpoints, and increased apoptotic effect need to be translated to claims for survivorship, toxicity and quality of life.
Acceptance will also depend upon cost; 
ANALYTICAL AND CLINICAL EVALUATIONS OF THE NGS TEST
In presenting evidence for the technical merits of the NGS test it is important that the submission makes the distinction between evidence to support its analytical validity and evidence for its clinical validity. The former refers to the test's ability accurately and reliably to detect variants (e.g., mutations, copy number variations) when they are present while the latter refers to the ability of the test to associate the variant with the presence or absence of the target phenotype. Thus, for DNA tests analytic validity requires establishing the probability that the test will be positive when a particular sequence of analyte is present (analytic sensitivity) or the probability it will be negative when sequence is absent (analytical specificity). The accuracy and reliability of the test, through replication in patient samples, is critical.
Similarly, the assessment of clinical validity rests upon sensitivity and specificity, but with an assessment of positive and negative predictive values, with account taken of prevalence, potential heterogeneity and penetrance. Once again, the issue is one of accuracy: is the genetic variant (or variants) being analyzed related to the presence or risk of the target disease. In October 2014 the Food and Drug Administration (FDA) published a draft guidance for the oversight of laboratory developed tests (LDTs). It was proposed that the FDA would oversee the quality of these tests alongside CMS. Given some confusion over the respective roles of the FDA and CMS with potential duplication an interagency taskforce was set up to collaborate on the oversight of LDTs. The position taken by the FDA is that its oversight will assure the tests are analytically and clinically valid. The taskforce has yet to report.
If the proposed FDA framework is accepted CMS through CLIA will ensure quality through its focus on laboratory operations and the testing process while the FDA will contribute to quality standards by enforcing compliance with the agency's quality systems regulation of the design and manufacture of, in this case NGS tests. The FDA view is that NGS tests are best considered as medical devices. Under section 201(h) of the Federal Food Drug and Cosmetic (FD&C) Act a product will be regulated as a medical device and is subject to premarketing and post-marketing regulatory controls if it is 30 . Under this amendment the FDA assigns in vitro diagnostic devices (IVDs) to one of three classes that correspond to the level of risk the IVD presents to patients and the public (Classes I through III). In Class III IVDs (where in vitro NGS tests are likely to be assigned), the IVD presents the highest level of risk and should be subject to premarket approval, post-market and other controls to ensure the tests can be used safely and effectively. The primary risk of is that of an undetected inaccurate test result resulting from both false negatives and false positives. The former could lead to unnecessary or the delay of necessary medical proceduresincluding a false positive flag for a repositioned or new drug regimen; the latter equally could lead to injury or death from the unchecked progression of disease. Both, as Schulen points out, could lead to unnecessary costs. Among the tests that the FDA considers high risk are those for companion diagnostics. Presumably, the concern for injury and death could apply equally well to the therapy options matched by the NGS platform to mutations or mutation clusters.
To ensure a reasonable assurance of safety and effectiveness, the benefits of a test will have to outweigh the risks it poses and that it will provide clinically significant results. For premarket approval there needs to be an independent demonstration of safety and effectiveness. The test has to achieve (i) a satisfactory analytical performance or validity in detecting pre-specified markers and (ii) a satisfactory clinical performance or validity demonstrating that the marker has a clinical significance in correlating with a disease or condition or with the ability to predict a therapeutic response to a drug.
Most tests under Class III would need 501(k) clearance.
The evidence presented to support analytical and clinical validity should conform to standards in place or standards proposed by the Food and Drug Administration (FDA). While these standards (and those presently proposed as guidance) apply to medical devices, those making the submission (or developing an NGS test) should assume, in the absence of agreed standards and processes, that the test will be considered a medical device for the purpose of the health system assessors.
Molecular Diagnostic Services Program (MolDx)
In 2011 CMS contracted to establish the Molecular Diagnostic Services Program (MolDx) through Palmetto GBA 31 . The purpose of this program was to:
• establish a unique registration identification of molecular diagnostics tests to facilitate claims processing and track utilization • to establish clinical utility expectations • to complete technical assessments of published test data to determine clinical utility and coverage • establish reimbursement for gene and gene components that meet Medicare covered service criteria
As of October 2016, MolDx had approved 152 tests for gene and gene components that met Medicare criteria for a covered service.
The clinical test evaluation process is in two parts (i) the evaluation of analytical and clinical validity and (ii) the evaluation of clinical utility 32 . To meet Medicare 'necessary and reasonable criteria' the test must meet both evaluation standards. Performance standards have been established by MolDx for analytical validity. These include analytical specifications for comprehensive genomic profiling 33 , analytical specifications for qualitative tumor only somatic variant detection using circulating tumor DNA.
The fact that a test has met the standards for the medical necessity review and registration under the Molecular Diagnostic Services Program (MolDx) -and consequently received national coverage by Medicare -does not mean that those making the submission can put evidence for analytical and clinical validity to one side. Although it is not the policy of the MolDx to comment on failed applications, it is important to advise on whether the application for this test has been put to one side.
When evaluating claims for clinical utility The MolDx team reviews each clinical trial presented to support claims for clinical utility. The trial data, to demonstrate the strongest clinical utility trial as opposed to other trials are classified as:
(1) mCTD3A: A randomized prospectively controlled trial that directly demonstrates that a therapeutic intervention based on test results leads to statistically and clinically significant improvement in patient outcomes compared to currently accepted standard of care. (2) mCTD3B: A prospective-retrospective trial using archived samples from a previously reported prospectively controlled trial to demonstrate that treatment based on a molecular test result in a specified patient population is associated with improved outcomes in a statistically and clinically significant manner versus a currently accepted standard of care.
(3) mCTD2A: A prospective observational study enrolling patients in a registry, treating according to a defined pathway using a molecular test as an integral part of a care plan and demonstrating statistically and clinically significant improvement in healthcare outcomes versus a currently accepted standard of care. (4) mCTB2B: Retrospective data modelling using large data sets to demonstrate statistically and clinically significant improvement in healthcare outcomes when a given molecular test guides treatment versus a standard of care. (5) mCTD1; Retrospective observational studies that do not stipulate treatment pathways or follow-up results based on results from the molecular test (6) mCTD0: Preclinical studies where the data are from animal or in vivo experiments or related studies or trials
If the level of evidence presented is below mCTD2B then the application will be rejected; although it is not clear what happens if the evidence based presented includes a mix of studies or where pre-clinical studies are linked to accepted studies.
Prospective FDA Standards for NGS Tests as a Medical Device
In July 2016 the FDA issued a draft (i.e., non-binding) guidance for regulatory oversight of NGS sequencing in vitro diagnostics 34 . While draft guidance was directed to whole exome DNA sequencing or targeted DNA sequencing NGSbased tests for diagnosing germline diseases or other conditions arising from inherited or de novo germline variants, the standards required are indicative of those the FDA might propose for somatic diseases. The recommendations cover (i) the design, development and validation of NGS-based tests and (ii) FDA-recognized standards for regulatory oversight of those tests.
It should also be noted that the FDA already has in place standards for evaluating diagnostic tests 35 . This guidance is intended for the submission of premarket notification (510(k)) and premarket approval for diagnostic devices or tests where there two possible outcomes: positive or negative. These standards are important because they provide more detail on benchmarks for assessing diagnostic performance. The benchmarks are: (i) comparison to a reference standard defined as the 'best available method for establishing the presence or absence of the target condition'; and (ii) non-reference standards. The benchmark will determine which performance measures are appropriate.
Reference standards are those agreed and adopted by 'opinion or practice within the medical, laboratory or medical community'. This distinction is important in precision medicine as it points to the importance of a consensus opinion in defining target patient groups for reporting clinical trial results and for the assessment of prognostic claims from NGS tests. The FDA recommends that before proceeding they should be consulted to ensure the reference standard meets the agency needs.
Even so, these standards are a long way from standards for NGS tests. Meeting standards for analytical and clinical validity are only a necessary, not a sufficient condition for approval of an NGS test as a medical device. The issue which is probably most vexing is how to evaluate the merits of competing tests. If NGS platforms generate different outputs, then the FDA should possibly consider minimum response standards at both the aggregate and pathway level (in effect to weed out the 'duds' and tests which have a high proportion of 'duds'). It seems possibly unreasonable to put the burden on health care systems; so perhaps, if the FDA adopts a more laissez faire approach, the onus should be (as is proposed here) for test developers and vendors to make the comparative case for their product.
It is worth emphasizing the FDA perspective as it raises the questions that an assessment by health care decision makers should address as an NGS-based test for clinical use will typically include reagents, consumables, instruments and software. The presence of one or more of these will be dictated by the workflow and functioning of the test. It is important, therefore, to detail the steps in the test process. These may include: (i) specimen collection and acceptable types for processing and storage; (ii) DNA extraction; (iii) DNA processing and library preparation; (iv) the regions of the genome, including genes and variants, that are interrogated by the test; (v) generation of sequence reads and base calling;
(v) variant classification/interpretation and (vi) preparation of test report.
At the same time, the test may involve manual variant interpretation. If this is the case then the technical description should include standard operating procedures (SOPs), decision algorithms and supplementary test components.
It is important that the submission, in particular for tests supporting next generation sequencing, includes a technical description of the predictive platform. Consider predictive simulation modeling, for example, where an in silico platform incorporates integrated networks of signaling and metabolic pathways through aggregating functional relationships between proteins and predicts mechanisms using drug combinations that interact to reduce viability, proliferation and other endpoints through the creation of patient avatars 36 . The platform needs to be described and should include, in this instance, how the effects of drugs or drug combinations are selected and applied from a library of molecularly targeted drugs to short-list potential repurposed or novel drug candidates.
Information should also be provided on how the library is curated, aggregated and interpreted in evaluating linkages. Although there is no requirement here that the library or, as described by the FDA, a 'genetic variant database' should be publicly available, the standards proposed for recognition by the FDA of a genetic variant database as a source of valid scientific information to support claims for the analytical and clinical performance of a test should be met. Two standard operating procedures are critical:
• procedures for the curating, aggregating and interpretation of high quality valid scientific evidence to support claims for the analytical and clinical performance of the platform • procedures for updating inputs and maintaining the stability and architecture of the platform content and processes
If the test manufacturer employs third parties to collect samples and undertake assessments, the role of these should be identified 
Possible FDA Requirements in Developing an NGS Test

TREATMENT PATHWAY AND AGGREGATE PERFORMANCE CLAIMS
As described briefly in the introduction to this commentary, a key distinction in validating claims for the reimbursement and placement of an NGS test is between (i) the overall performance of the test against the standard(s) of care that characterize the proposed intervention point for the test in the treatment pathway for a specific disease and (ii) the contribution of the most frequently recommended therapy combinations that the test administrator reports for the individual platform assessments.
Competing claims for NGS tests will rest, therefore, on both aggregate performance and patient response at the therapy choice level. This distinction has a number of implications: (i) there is no certainty that different platforms will generate similar or the same therapy choice recommendations; (ii) adverse events and toxicity may differ between treatment pathways so that risk mitigation may be driven by pathway therapy choices; (iii) if drug-to-drug interactions are a concern, they are best explored at the pathway level; (iv) response to therapy may vary by therapy choice which may lead to qualifications of indication for use; (vi) resource utilization and cost claims may vary by therapy pathway so that the distribution of patients by therapy pathway may be a major, if not the principal, determinant of therapy costs; (vii) adherence and persistence with therapy may differ by pathway, suggesting possible pathway specific interventions to support therapy utilization; and (viii) the impact of comorbidities and their impact on the overall polytherapy burden may qualify response to therapy through adherence and persistence.
COMPARATIVE NGS EVALUATIONS
It is unlikely that a formulary committee or health system will only evaluate a single test. With the potential commercial benefits of test adoption, it is more than likely that decision makers will be faced with a number of competing tests. Given this, it is important that the information requested for each test is to a fixed standard that allows a comprehensive assessment of competing claims for clinical and analytical validity.
In the unlikely event that there has been a head-to-head comparison of the analytical and clinical validity of the proposed test against one or more actual or potential comparator tests, a submission should include: Techniques for assessing the analytical validity of NGS tests need not be restricted to those data elements proposed in the FDA guidance. There are a range of possible tests that can supplement claims for sensitivity and specificity and prevalence corrected claims for positive and negative predictive value with the appropriate confidence intervals.
INTEGRATION IN CARE PATHWAYS
To date, there are only a few treatment guidelines that have included the option of genomic testing as an element in care pathway decisions. As claims for the introduction of NGS tests as an integral part of the process of care will likely run ahead of their introduction into treatment guideless, it is important that those proposing a role for NGS in disease states (by stage of disease for a target population) present a robust, evidencebased case for the test (e.g., to meet NCCN standards).
The test submission should detail, for each disease state, the potential placement of the test in the process of care together with a consensus definition on the target intervention group. Given the focus of precision medicine on cancer, in particular late stage cancer interventions, submissions should utilize as their template for test placement in oncology the treatment pathways and clinical guidance developed by the NCCN 37 In non-oncological disease states the guidelines should be latest proposed by the respective professional associations.
While it is unlikely that a professional group responsible for treatment guideline development would nominate a particular NGS test, it is possible that they would set the minimum performance standards required for an NGS test to be accepted into clinical practice for target patient populations.
The appropriateness, acceptance or otherwise of claims for the analytical and clinical validity of an NGS test are only relevant in the context of the 'footprint' of the test. Is the test designed to: (i) apply across the board to a range (or any number) of disease states (ii) apply to a single disease state (iii) apply to a target tumor across a range (or any number) of disease states (iv) apply to a target tumor in a single disease state Each of these footprints should be supported by an evidence base which meets the standards for the quality of the evidence as well as claims for the test which are credible, evaluable and replicable in the restive molecular targets. This is seen in the case of the footprint (i) where the claim is for the test across either 'any' disease state or for a sub-set of disease states. Irrespective of the breadth of the claim, a formulary committee is faced with the question of whether limited claims for the test in a sub-set of disease states can be assumed to be sufficient to accept the test as the basis for molecular targeting in disease states where the evidence is lacking. Clearly, it would be unwise, given issues of performance and safety outcomes, to assume that this is the case. Formulary committee, therefore, should request substantive and credible evidence for claims in each disease state. This should apply to claims directed towards the test's target population by stage of disease.
An important caveat is the whether the test utilized in a particular trial design is the test proposed by a vendor for approval by the health care system. Claims for analytical and clinical validity are only acceptable if the claims for analytical and clinical validity between competing tests to identify one or more molecular targets and link these to proposed therapy interventions are compatible for all target treating populations within the test 'footprint'.
No test can claim to have identified all potential molecular markers and the potential interactions between variants with their impact on patient response. Even within a given histologic tumor multiple markers may be present. In the unlikely event that a manufacturer underwrites a headto-head comparison with competing tests or at least the most likely comparator for a target population in one or more disease states, an assessment of competing claims will rely upon indirect comparisons. While this is a common situation in drug product evaluations, where there is an established methodological literature to support indirect comparisons, comparing competing tests adds a further level of complexity.
Unless an effective indirect comparison between competing tests is undertaken, payers have no basis for assessing the merits of claims made by a developer/vendor. This situation is made more difficult given the footprints of competing tests and the number of tests that will be competing for the attention of payers. Even with common agreement on analytical and clinical validity standards in the case, for example, where a test is considered a medical device and the FDA takes responsibility for class III 501(k) evaluations, there is no certainty that competing tests will generate similar variant profiles for therapy interventions. This is a situation which will make indirect comparisons more complex if there are options for matching therapies to specific variants given individual NGS test results.
EVIDENCE BASE FOR NGS TESTS
At the present time, while there is accumulating evidence for the analytical and clinical validity of NGS tests, although minimum performance standards for accuracy have yet to be agreed, there is little evidence from either randomized clinical trials or well conducted observational studies. Formulary committees and other health decision makers are understandably reluctant to support a specific NGS test not only with the absence of, for example, umbrella trial designs matching test results against the standard of care in target populations but, equally importantly, comparative assessments of competing tests.
Randomized Clinical Trials
Required performance criteria for NGS tests in target patient populations are no different from the criteria that would apply to non-NGS treatment options. The test would be judged in comparative terms against the outcomes that are typically applied in therapy impact assessments within that disease group and by stage of disease.
In late stage oncology interventions where there are a range of potential roles for NGS evaluations and their contribution to the process of care, clinical standards for outcomes are well established. These capture both the primary outcomes these outcomes -progression-free survival, overall survival, relapse, toxicity -and secondary endpoints that focus on patient reported outcomes, including functional status, pain and both generic and disease specific quality of life measures.
Given that the adoption of NGS tests is at any early stage and that the evidence base to support disease and target-group specific NGS claims is limited, developers of NGS tests face three hurdles. First, to invest in well-designed randomized clinical trials to compare NGS interventions against the standard of care in target disease states; second, to develop protocols to validate claims in treatment practice; and, third, to develop a robust methodology to compare the effectiveness of competing NGS tests.
Although standards for randomized clinical trials are well established, the NGS trial design is necessarily challenged by heterogeneity within patient populations. It is important to recognize the diversity of trial designs that have been proposed under the overall 'umbrella' designation to account for (i) inter and intra patient tumor molecular heterogeneity and (ii) tumor progression and the capture of intra-patient heterogeneity over time 38 . There is a developing literature and examples of alternative umbrella trial designs (e.g., the PANGEA IMBBP Phase1/2 trial design for gastro-esophageal adenocarcinoma) 39 . Given the complexity of these designs in terms of both treatment pathways, definition of standard of care, target drug combinations and variations in the incidence of biomarkers from exome sequencing in target trial populations, the structure of the various trials needs to be adequately described. When the results of trials are reported they should reference claims for analytical and clinical validity to support the structure of the trial and the individual therapy pathways.
Reporting randomized trials, required data elements:
• 
Systematic Reviews and Meta-analyses
Submissions to support an NGS test submission to a health system or formulary committee should not rely upon one or two randomized trials. These should meet the PISMA-P 2015 standards. The complexity of gene expression and the range of platforms utilized to identify recommended therapy options means that the greatest credibility will be afforded the test with the most credible evidence base.
Submissions to formulary committees should report on a systematic review of all randomized trials for the specific test as well as for potentially competing tests. This sets the stage for indirect comparisons of competing NGS claims. Again, the systematic review should be restricted to the evidence for the target population. Given inter and intra patient genomic heterogeneity, it cannot be assumed that claims for the NGS test in one target population can be used to support prospective claims for efficacy or effectiveness in other target populations. Nor can it be assumed that test claims from trials reported for the target treating population, given molecular heterogeneity, need necessarily translate to the health system's target population. At the same time there needs to be a clear statement of the justification for an expected 'optimal' monotherapy or combination therapy choice to matching individual patients to their respective biomarkers.
Observational Studies
Observational studies include (i) prospective studies that are protocol driven and are intended to evaluate claims made from models and (ii) retrospective studies that are intended to evaluate claims from integrated databases. It is unlikely, at this time, that retrospective observational studies will play a substantive role in evaluating claims for specific NGS tests until integrated data sets expand the coverage to include identifiers for specific NGS tests and expand their capture of genomic information to include variant or mutation classifications. The most likely source of data will be from results reported for prospective observational studies that adhere to a protocol submitted in support of a specific NGS test. Indeed, the importance of evidence from protocoldriven observational studies, compared to the costs and time involved in undertaking a randomized trial, will place a premium on developers or vendors of NGS tests to engage with health care systems to partner in prognostic claims validation within target populations.
The purpose of the prospective protocol driven observational study is twofold: (i) to evaluate the claims made for the NGSdirected therapy choices for both the targeted patient population and patients assigned to specific therapy groups as 'individualized' packages and (ii) to evaluate claims for resource utilization and, potentially, cost savings again for the targeted patient population and the therapy groups.
The point to emphasize is that unless claims utilizing NGS tests can be validated by health care systems, there is no basis for reimbursement or an agreement on pricing. Randomized clinical phase 2 and phase 3 trials are a key input, but these need to be followed up with observational tracking studies within target patient groups. Accumulating evidence from tracking studies across similar target populations in health care systems will, hopefully, provide a robust and believable evidence base for the individual NGS platform.
Reporting observational studies: required data elements:
Modeled Study Claims
Claims evaluation involving a protocol assessment will typically rely upon cost-effectiveness or cost-utility models. These would take a short term focus with the results reported in a timeframe relevant to decision makers. The model may be structured around a clinical trial or it may extrapolate from that trial. Claims generated by models are only acceptable if they are credible, evaluable and replicable. The structure of the model would probably replicate and extrapolate from the design of umbrella trials reporting for the particular NGS test. Treatment pathway criteria should be justified (e.g., high frequency therapy choice clusters). Inputs to the model would be based upon the results of the systematic review of the trial literature for that test together with those inputs from a review of the literature where trial primary and secondary outcomes fail to capture the particular parameter (e.g., specific patient reported outcomes such as quality of life).
Standards for model building are well established, to include the treatment of structural and parameter uncertainty 40 . Care should be exercised, however, in adopting standards of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) as these include study designs that are not intended to generate evaluable claims 41 42 43 .
It is expected that the modeled claims made for the NGS package in the targeted patient groups will be presented as part of the submission package (see below) by the NGS developer or vendor. Claims, both clinical and cost-effective (or cost-utility) would conform to the standards of normal science: they would be credible, evaluable and replicable. Unlike traditional cost-effectiveness claims, the claims proposed by the developer would be expected to take account of the tumor heterogeneity in the target population in the choice of treatment pathways to compare to standard(s) of care pathway(s).
At the same time, however, a model would have to accommodate potential confounding factors such as the presence of co-morbidities, drug-to-drug interactions both between the tumor specific drugs as well as with those assigned for other conditions. Within the timeframe for the model, claims should attempt to accommodate adherence and persistence behavior, non-tumor related morbidity and mortality and anticipated responses involving possible retesting and drug therapy reallocation to accommodate tumor progression. The lifetime of the modeled claim will have to be consistent with ongoing reporting of outcomes to a formulary committee. Unless the anticipated timeframe for survivorship is 'short', lifetime cost-utility claims would be of no interest as they would lack credibility for evaluation and replication.
Any modeled claim for NGS based-interventions has to be comparative. The model would then have to accommodate the standard of care reference point, together with (again over the lifetime of the model) interventions to accommodate the expected disease progression. In some instances, a developer or vendor may attempt to model competing platforms for the target population. Again, comparative claims would have to be credible and open to evaluation.
NGS UPTAKE AND IMPLEMENTATION
Modeling a claims for the anticipated impact of NGS platform indicated treatment pathways should also take account of (i) the uptake of the NGS test by the treating physicians (i.e., ordering the test) and (ii) the implementation of the test (i.e., following the recommended therapy pathways for matched patients). Evidence to date, admittedly anecdotal, would suggest that less than fifty per cent of treating physician order tests with even fewer actually attempting to implement the test results. At the same time, we have no data on patterns of adherence and persistence with a test-directed regimen. This situation is made more opaque by the absence of data on the monitoring of patient responses to a therapy choice and the criteria that physicians may follow to order further tests in response to patient relapse and the likelihood of adverse tumor progression.
Reporting requirements should include:
Implementing NGS Test Results
A question that has to be addressed with the advent of NGS is how the treating physician is to act on recommendations made for a repositioned FDA approved therapy for an individual patient. As it is unlikely that there will be a common repositioned therapy (or therapies) for those failing or non-responsive to the standard of care, one role of a formulary committee or health system in approving an NGS platform is to request developers for their recommendations for repositioning are to be translated into clinical practice decisions and how they would assess and report relative benefits/harms. The NGS developer should agree with the health system the content of reports to be provided to treating physicians to guide therapy options and report safety issues.
One approach that should be considered is the heuristic Oxford Centre for Evidence Based Medicine (OCEBM) levels that cover the entire range of clinical questions that a clinician might ask. The OCEBM system allows clinicians and patients to appraise evidence for prevalence, accuracy of diagnostic tests, prognosis, therapeutic effects, rare harms, common harms, and usefulness of (early) screening 44 .
Another and more recent approach is the GRADE Evidence to Decision (EtD) framework 45 . This should be considered as a possible model for informing physicians and supporting clinical decisions. The EtD approach is to assist physicians to use evidence in a structured and transparent way, linking to practice guidelines and going from evidence to decision.
Feedback on Test Performance
The credibility of claims and agreement on the place of a specific NGS test in therapy across a number of disease states will require tracking outcomes to be reported back in a timely fashion to health care decision makers. The protocol that is drafted and agreed with the health system should detail the frequency and content of reports on the performance of the test. Confidence that NGS recommendations have a credible role in treatment decisions must be evidence based. They should be reported by the developer or vendor to the health care system. They should also be made available in the public domain through peer reviewed publications and web sites. It is important, therefore that the claims assessment protocol that is agreed with a health system details which claims are to be reported, how they are to be reported and the timeframe for reporting.
THE NGS SUBMISSION
Submissions to support NGS adoption should meet a common evidentiary standard. The following outline is proposed: 
CONCLUSIONS
The purpose of this commentary has been to raise a number of key questions regarding (i) the evidence base for NGS claims; (ii) the standards required to support NGS claims and (iii) the standards required for their introduction to clinical practice.
The current evidence base is inadequate. There is not only limited evidence for the clinical utility of NGS tests but a limited appreciation of the steps required to ensure that claims made are validated and that risks to patients are adequately protected. While there is little doubt that the various NGS tests will be classified as medical devices, we have no direction from agencies such as the FDA as to their role beyond certifying the test meets standards for analytical and clinical validity. Unlike the NICE DAP evidence standards where modeled claims for costs and outcomes are requested, there is no evidence to date that the FDA will attempt further to regulate test claims and the choice of mutation linked therapies. Even so, concerns with safety and adverse events with what are likely off-label use of a range of pharmaceutical products may force the FDA to demand stronger evidence for clinical utility, to include risk-mitigation and monitoring requirements.
In the absence of standards to evaluate and monitor the claims from NGS platforms, the proposal here is that formulary committees and health systems take the initiative. A range of questions that formulary committees might reasonably ask are detailed, together with the proposal that submissions for NGS tests should not only be target patient specific but should be accompanied by an assessment protocol.
At the same time, NGS developers and vendors will face an uphill struggle to convince health care systems, treating physicians and guideline developers to introduce NGS test options into clinical practice. While the evidence base (as emphasized) is just too limited, this situation will likely be compounded by the number of competing tests and the need, from both clinical and cost-effectiveness perspectives, to report on the validity of test claims for well-defined reference target populations and for the mutation-linked therapy choices. Whatever claims are made for individual NGS tests, to include claims for the superiority of one test over another, the claims made must be credible, evaluable and replicable. Health system decision makers will expect no less.
